Jacobio Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million

Reuters

Mar 10

<a href="https://laohu8.com/S/01167">Jacobio</a> Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million

Jacobio posted FY 2025 revenue of RMB53.5 million, down 66% from a year earlier, attributed to its License-Out Agreement and related services agreements. FY 2025 R&D expenses fell 43% to RMB188.6 million, which the company said was mainly due to the absence of large-scale pivotal trial clinical costs as pivotal trials for glecirasib and sitneprotafib are managed and fully funded by partner Allist. FY 2025 administrative expenses decreased 20% to RMB34.4 million, driven by lower employee benefit expenses and tighter discretionary spending. FY 2025 loss narrowed 6% to RMB146 million. Jacobio said it ended FY 2025 with RMB1.13 billion in cash, bank balances and capital-protected structured deposits, while interest-bearing bank borrowings rose to RMB94.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047664), on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618514449"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618514449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618514449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618514449","market":"fut","top_or_hot":-1,"title":"Jacobio Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio posted FY 2025 revenue of RMB53.5 million, down 66% from a year earlier, attributed to its License-Out Agreement and related services agreements. FY 2025 R&amp;D expenses fell 43% to RMB188.6 million, which the company said was mainly due to the absence of large-scale pivotal trial clinical costs as pivotal trials for glecirasib and sitneprotafib are managed and fully funded by partner Allist. FY 2025 administrative expenses decreased 20% to RMB34.4 million, driven by lower employee benefit expenses and tighter discretionary spending. FY 2025 loss narrowed 6% to RMB146 million. Jacobio said it ended FY 2025 with RMB1.13 billion in cash, bank balances and capital-protected structured deposits, while interest-bearing bank borrowings rose to RMB94.8 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047664), on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio posted FY 2025 revenue of RMB53.5 million, down 66% from a year earlier, attributed to its License-Out Agreement and related services agreements. FY 2025 R&amp;D expenses fell 43% to RMB188.6 million, which the company said was mainly due to the absence of large-scale pivotal trial clinical costs as pivotal trials for glecirasib and sitneprotafib are managed and fully funded by partner Allist. FY 2025 administrative expenses decreased 20% to RMB34.4 million, driven by lower employee benefit expenses and tighter discretionary spending. FY 2025 loss narrowed 6% to RMB146 million. Jacobio said it ended FY 2025 with RMB1.13 billion in cash, bank balances and capital-protected structured deposits, while interest-bearing bank borrowings rose to RMB94.8 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047664), on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL3cp7Fl:1","article_id":"2618514449","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618514449","pubTimestamp":1773154507,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jacobio posted FY 2025 revenue of RMB53.5 million, down 66% from a year earlier, attributed to its License-Out Agreement and related services agreements. FY 2025 R&D expenses fell 43% to RMB188.6 million, which the company said was mainly due to the absence of large-scale pivotal trial clinical costs as pivotal trials for glecirasib and sitneprotafib are managed and fully funded by partner Allist. FY 2025 administrative expenses decreased 20% to RMB34.4 million, driven by lower employee benefit expenses and tighter discretionary spending. FY 2025 loss narrowed 6% to RMB146 million. Jacobio said it ended FY 2025 with RMB1.13 billion in cash, bank balances and capital-protected structured deposits, while interest-bearing bank borrowings rose to RMB94.8 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","01167":"加科思-B","BK1161":"生物科技"},"translate_title":"雅可比奥制药2025财年收入下降66%至5353万元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":0.9},"content_text":"Jacobio Pharmaceuticals FY2025 revenue fell 66% to CNY53.53 million\n    \n\n        Jacobio posted FY 2025 revenue of RMB53.5 million, down 66% from a year earlier, attributed to its License-Out Agreement and related services agreements. FY 2025 R&D expenses fell 43% to RMB188.6 million, which the company said was mainly due to the absence of large-scale pivotal trial clinical costs as pivotal trials for glecirasib and sitneprotafib are managed and fully funded by partner Allist. FY 2025 administrative expenses decreased 20% to RMB34.4 million, driven by lower employee benefit expenses and tighter discretionary spending. FY 2025 loss narrowed 6% to RMB146 million. Jacobio said it ended FY 2025 with RMB1.13 billion in cash, bank balances and capital-protected structured deposits, while interest-bearing bank borrowings rose to RMB94.8 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047664), on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}